J&J beats profit estimates but coronavirus fuels forecast cut

Johnson & Johnson on Tuesday beat analysts' estimates for first-quarter profit on higher sales of its cancer drugs and consumer products including Tylenol, while cutting its full-year forecast due to coronavirus shutdowns. Shares of the company, which boosted its quarterly dividend by 6.3% to $1.01 per share, rose 3.3% to $144.45 in trading before the bell. Johnson & Johnson is the first major U.S....